A Longitudinal Study to Evaluate an Extracellular Matrix (MatriStem®) for the Treatment of Diabetic Foot Ulcers

NCT02750280 | Completed

• 1 other identifier: CA2014-002
• Study Type: interventional
• Target: 17
• Locations: 1 country
• Sites: 1

Brief Summary

This ia a prospective controlled longitudinal study to evaluate the effects of MatriStem® plus standard local wound care versus standard local wound care alone in the treatment of diabetic foot ulcers (DFUs), as assessed by incidence of complete wound healing by 16 weeks and ulcer recurrence with a 2 year follow-up.

Conditions

Neuropathic Diabetic Foot Ulcer

Outcome Measures

Primary Outcomes (1)

• Incidence of wound healing

  16 weeks

Secondary Outcomes (1)

• Incidence of ulcer recurrence

  1 year

Study Arms (2)

Urinary Bladder matrix (UBM)

EXPERIMENTAL

UBM covered with silicone foam dressing plus total contact cast

Device: MatriStem® [Urinary Bladder Matrix (UBM)]

Standard Care

ACTIVE COMPARATOR

Silicone foam dressing plus total contact cast

Device: Mepilex® [Silicone foam dressing]

Interventions

MatriStem® [Urinary Bladder Matrix (UBM)] DEVICE

Porcine derived urinary bladder extracellular matrix

Also known as: MatriStem

Urinary Bladder matrix (UBM)

Mepilex® [Silicone foam dressing] DEVICE

primary wound dressing

Also known as: Mepilex

Standard Care

Eligibility Criteria

• Age: 18 Years - 85 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male and female subjects 18-85 years of age with diabetes mellitus (type 1 or type 2)
• Subject's foot ulcer is on the plantar surface of the foot.
• DFU has not healed after more than2 months of SOC treatment administered
• Subject's ulcer must be Wagner type 1 or 2 (uninfected, extending through the dermis and into subcutaneous tissue or granulating but without exposure of tendon, bone, or joint capsule.
• Subject's wound is free of necrotic debris (post debridement) and clinical infection, should be comprised of healthy, vascular tissue.
• Subject's Ankle-Brachial Index (ABI) by Doppler method is ≥ 0.7
• The subject has adequate circulation to the foot to allow for healing. This must be demonstrated by methods described in section 5.1
• Subject's diabetes is under control as determined by the Investigator
• Study subject must be reliable, responsible and able to visit the clinic weekly for the full 16 week period. The subject is willing and able to tolerate TCC. Subject is willing to comply with the monthly follow-up regimen for 32 weeks (8 months) The subject is able to return to the clinic if ulcer recurrence occurs
• Subject or his/her legal representative has read and signed the Institutional Review Board (IRB) approved Informed Consent form before treatment
• No active malignancy except non-melanoma skin cancer

You may not qualify if:

• Subject has clinical evidence of gangrene on any part of the affected foot
• Subject has a Wagner type 3 or greater ulceration
• The subject's ulcer is due to a non-diabetic etiology, Ulcers of arterial, venous stasis, pressure, radiation, traumatic, rheumatoid, vasculitis, collagen vascular disease, or other non-diabetic etiologies
• Subject has a known sensitivity to bovine or porcine derived devices
• Subject has one or more medical condition(s) including renal, hepatic, hematological, neurologic, or immune disease that in the opinion of the Investigator would make the subject an inappropriate candidate for this wound healing study
• Subject has or has had a malignant disease (other than cutaneous epithelioma) not in remission
• Subject is receiving oral or parenteral corticosteroids, immunosuppressive or cytotoxic agents, or is anticipated to require such agents during the course of the study
• Subject has chronic osteomyelitis as determined by high resolution ultrasonography
• Subject's ulcer is infected or accompanied by active cellulitis as determined by the Investigator
• Subject has any condition(s) that seriously compromises the subject's ability to complete the study
• Subject is pregnant or lactating at the time of treatment
• Subject has received growth factor therapy (e.g. autologous platelet-rich plasma gel, bacaplermin, bilayered cell therapy, dermal substitute, extracellular matrix) within two weeks of enrollment. If Santyl or any other collagenase is used, a subject must have a washout period of 2 weeks before MatriStem® can be applied.
• Subject is currently receiving or has received radiation or chemotherapy within 3 months of randomization
• Subject has a history of alcohol or drug abuse
• Subject allergic to a broad spectrum of primary \& secondary dressing materials, including occlusive dressings and the adhesives on such dressings.

Sponsors & Collaborators

• Calvary Hospital, Bronx, NY: lead
• Integra LifeSciences Corporation: collaborator

Study Sites (1)

Calvary Hospital Center for Curative and Palliative Wound Care

The Bronx, New York, 10461, United States

Location

Study Officials

• oscar Alvarez, PhD

  Calvary Hospital Director, Center for curative and palliative wound care

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Director, Center for Curative & palliative Wound Care

Study Record Dates

• First Submitted: April 21, 2016
• First Posted: April 25, 2016
• Study Start: June 1, 2015
• Primary Completion: December 1, 2015
• Study Completion: December 1, 2015
• Last Updated: April 25, 2016

Record last verified: 2016-04

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)